about
Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone massFKBP51 reciprocally regulates GRα and PPARγ activation via the Akt-p38 pathwayGlucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN.FKBP51 controls cellular adipogenesis through p38 kinase-mediated phosphorylation of GRα and PPARγ.Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice.FKBP51-a selective modulator of glucocorticoid and androgen sensitivity.Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ).PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption.PPARδ binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats.Bone and fat: a relationship of different shades.Marrow Adipose Tissue: Skeletal Location, Sexual Dimorphism, and Response to Sex Steroid Deficiency.FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation.Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α.Reciprocal regulation of PPARγ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5.High bone mass in adult mice with diet-induced obesity results from a combination of initial increase in bone mass followed by attenuation in bone formation; implications for high bone mass and decreased bone quality in obesity
P50
Q27334866-1FFB630B-4E90-4C23-A11D-AD03A31B147CQ28391433-9B3FAC35-9B62-4ECA-894C-D690E1269CABQ33793042-CB0C6CD4-C7E7-4AC7-AF8A-2E17D5FB1C51Q33977397-0940ED54-013C-4F8E-A2CE-3D34E5253665Q33993835-E04AADA2-0B38-49B9-A65B-9540A7D1628CQ35165351-7C65186F-FF8C-4D04-9C86-8FB455D7B645Q35604703-AB494870-F21F-42AD-B083-3BFC85D18256Q37221508-2821CACB-3DA7-475E-A4AC-0AB143E65823Q37631653-809C0A3A-B214-42F8-AEAE-6D32D54FCECBQ38222551-3B8D8164-95F2-47A5-A3B7-DE620C513797Q41245485-852B4A65-4C22-45A9-BB79-96FA148C59A2Q41640775-E8F4ACC4-3E84-418E-82B8-5805D4BF96E7Q41778841-E0C14930-3F13-4F8F-851F-6676517EF936Q46080639-A4E74942-41B2-4A12-BF52-F1CC2BE557C5Q46420424-22659CF4-C576-44E5-8369-2564EE02D014Q47256544-F895DA9A-897B-4CE7-95E3-CE8DF5D91D36Q86506036-762E0A40-59C5-43CC-BA7E-22A211C6E430
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lance A Stechschulte
@ast
Lance A Stechschulte
@en
Lance A Stechschulte
@es
Lance A Stechschulte
@nl
Lance A Stechschulte
@sl
type
label
Lance A Stechschulte
@ast
Lance A Stechschulte
@en
Lance A Stechschulte
@es
Lance A Stechschulte
@nl
Lance A Stechschulte
@sl
prefLabel
Lance A Stechschulte
@ast
Lance A Stechschulte
@en
Lance A Stechschulte
@es
Lance A Stechschulte
@nl
Lance A Stechschulte
@sl
P106
P2038
Lance_Stechschulte
P21
P31
P496
0000-0001-9783-6194